Furthermore, two pilot studies in advanced colorectal cancer patients with wtKRAS demonstrated emerging KRAS aberrations in cfDNA during treatment with an anti-EGFR therapy [31, 32]. This evidence concerns the gene EGFR and colorectal cancer.